Objective Our objective was to quantify preferences and stated adherence for inhaled antibiotic treatments in cystic fibrosis (CF). Methods Adult CF patients and parents of pediatric patients in the US who were members of the Cystic Fibrosis Foundation and who had Pseudomonas aeruginosa at least twice a year completed an online, discrete-choice experiment survey (response rate 4.4 %). Respondents answered five treatment-choice questions evaluating pairs of hypothetical CF treatment profiles. Stated-adherence questions followed two randomly selected treatment-choice questions. Data were analyzed using random-parameters logit (RPL). For a combination of attribute levels, the utility is estimated by summing the relevant attribute-level parameter estimates. For the stated-adherence questions, we tabulated the changes in the percentages of respondents who would be 95 % adherent for various changes in inhaled antibiotic-medication administration features. Results The final sample was 271 adult patients and 209 parents. Switching from a 30-min nebulizer twice daily to a 10-min dry powder inhaler (DPI) twice daily was 6.3 times more important for patients and 2.0 times more important for parents than an improvement in dry cough side effect from moderate to mild. Stated adherence for respondents was 20-30 % greater for DPIs versus nebulizers. Conclusions Lower frequency of administration, shorter administration times for a given device, and milder dry cough appear to improve stated adherence to antibiotic treatment of CF lung infections.
Introduction
Cystic fibrosis (CF) is a life-shortening genetic disorder that results in pulmonary infection caused by the accumulation of obstructive mucus. Pseudomonas aeruginosa is the most common respiratory pathogen found in 50-70 % of CF patients and results in a decline in pulmonary function, frequent hospitalization, and increased mortality risk [1] [2] [3] . US CF treatment guidelines recommend the use of inhaled antibiotics for chronic P. aeruginosa infection [4] . However, adherence to inhaled antibiotics that use a nebulizer is low and ranges from 31 to 53 % [5, 6] . This may be because using a nebulizer has a significant treatment burden in terms of time required for set-up, administration, and cleaning and disinfecting [7] . Nebulizers also often require an external power source and refrigeration and have limited portability. Because they require a complex disinfecting procedure, most nebulizers become contaminated [8, 9] .
Non-adherence to inhaled-antibiotic treatment results in poorer health outcomes, including more frequent exacerbations and hospitalizations, more rapid disease progression, weight loss, greater absence from work or school and poor morale [10, 11] . There is evidence that non-adherence is related to the high treatment burden (in terms of time required for set-up, administration, and cleaning and disinfecting) [7, 12] . Patients have reported a mean of 108 min per day for managing their condition, including approximately 40 min per day using a nebulizer [7] . This figure indicates that patients do not take their inhaled antibiotics for the required duration each day. However, this finding is not surprising, as managing CF requires multiple medical treatments that take approximately 2-3 h to administer correctly each day [7] .
Alternative technologies, such as dry-powder inhalers (DPIs) could provide better adherence because of their shorter administration and maintenance times. To understand the impact of nebulizers and DPIs on patient satisfaction and stated adherence, we followed best practice [13] in designing and administering a discrete-choice experiment (DCE) (also known as choice-format conjointanalysis survey) to elicit patient and parent preferences and stated adherence for inhaled antibiotic-medication administration features.
Methods

Discrete-Choice Experiments
This study used a DCE survey to quantify patient and parent trade-off preferences for features of inhaled-antibiotic devices for treating chronic P. aeruginosa infections. This is a systematic method grounded in both psychology [14] and economics [15] for eliciting trade-offs to quantify the relative importance of treatment process features and health outcomes [16, 17] . This approach is based on the premise that treatments are composed of a set of attributes or outcomes such as mode of administration, effectiveness, and side effects and that the relative importance, satisfaction, or utility to patients of a particular treatment is a function of these attributes [18, 19] .
Survey Instrument
Respondent preferences for inhaled-antibiotic administration features for CF medications to treat chronic P. aeruginosa infection were elicited for five attributes, including device type (nebulizer, DPI), administration and cleaning time per use (15, 25 , and 30 min for nebulizer; 5 and 10 min for DPI), dosing frequency (two or three times per day), dry cough side effect (mild, moderate, severe), and personal cost per cycle ($100, $150, $250, $500). These five attributes were chosen to describe CF treatments after a review of package inserts and consultation with clinical experts via teleconferences to achieve the goals of the study. These five attributes were tested in face-to-face patient interviews to determine whether any treatment attributes of importance to patients had been omitted. The attributes were described using non-technical language [13] . The levels for each attribute were designed to encompass the range observed in clinical practice, as well as the range over which respondents were willing to accept trade-offs among attributes. The time ranges are specific to each device to avoid implausible combinations. Estimates for the relative importance of times for nebulizer and inhaler are reported separately below. Before answering the treatment-choice questions, respondents were told that the treatments worked equally well. Fig. 1 is an example of a treatment-choice question.
Stated-adherence questions for each treatment profile followed two randomly selected treatment-choice questions as shown in Fig. 2 . Patients were asked to state the likely adherence for themselves and a ''typical CF patient''. This so-called 'social valuation' format has been previously validated in survey research to reduce social acceptability bias [20] . This additional information thus allowed us to test for potential bias related to respondents providing socially acceptable responses. Parents were asked stated-adherence questions for their family, other families with a child with CF of the same age, and other families with a child with CF of a different age (B12 years or [12 years). The two categories for the other families with a child with CF was included because children aged [12 years usually administer the treatment themselves, whereas parents administer the treatment for children aged B12 years. In addition to the choice questions, the survey instrument also included questions about respondents' demographic characteristics and their experiences with CF and CF treatments.
Survey Testing
Semi-structured, face-to-face, 1-h interviews were conducted to test the survey instrument with a convenience sample of six patients and nine parents in Raleigh, NC, USA. In particular, these interviews aimed to test the clarity of the survey instrument, to confirm that the five attributes were important to respondents and that no salient attributes had been omitted, and to assess whether respondents were willing to accept trade-offs among these five attributes by implementing a simple bidding game [13] . We followed standard practices and asked respondents to read the survey out loud ('think aloud' method) and encouraged them to explain their rationale for selecting alternatives in the choice and stated-adherence questions. One major change implemented after the survey testing was to include three categories of stated-adherence questions The version of the survey adapted for parents who care for a child with CF had the third attribute as ''How often your child takes the medicine''. Parents were asked ''How often do you think your family and other families could follow the recommended time for taking the inhaled-antibiotic medicine for a 28-day treatment period?'' Parents were also asked to state the adherence level for three categories: (1) your family, (2) typical family with a child the same age, and (3) typical family with a child (aged 12 years or younger or older than 12 years) for parents because in exploring likely stated adherence for parents as stated above, we found very strong age effects, indicating significantly greater levels of stated non-adherence in teenagers than in younger children. Text changes were also made to the survey to improve respondent comprehension. There was no formal analysis of the qualitative data from the interviews. The final versions of the survey instruments can be found in the Supplementary Material.
Experimental Design
The combination of attribute levels included in each hypothetical treatment profile was determined by a main-effects D-efficient experimental design, generated using SAS version 9.2 [21] . The experimental design resulted in 60 treatment-choice questions. Respondents were randomly assigned to five of the 60 treatment-choice questions. The theoretical sample size was 200 respondents in each sample. The utility function was simply that choice is a function of the attribute levels. The D-error was 0.03556.
Study Sample and Data Collection Procedures
Patient and parent preferences for administration features, including dry-cough side effect and cost of CF inhaled-antibiotic medications were estimated for respondents residing in the USA. To be included in the study, respondents were required to be aged C18 years, have a self-reported physician diagnosis of CF, or be the parent of a pediatric patient (aged 6-17 years) with CF, and the patient must have stated that they have tested positive for P. aeruginosa in their lung culture at least twice a year (self-reported). Potential respondents were recruited from the members of the Cystic Fibrosis Foundation (CFF). A $25 donation was made to CFF on the respondent's behalf for each completed survey.
In October 2012, potential respondents were sent an invitation e-mail asking them to participate in the study; those who chose to participate accessed the self-administered online survey from a personal computer. Respondents were first screened to ensure that they met the inclusion criteria. Eligible respondents were informed of the potential benefits and risks of participation in the study and provided informed consent before completing the 25-min survey. Before the survey was fielded, the study design was reviewed and approved by the Office of Research Protection and Ethics at RTI International (Research Triangle Park, NC, USA).
Statistical Analysis
The responses to the treatment-choice questions were analyzed using random-parameters logit. The random-parameters logit is an improvement on the fixed-effects conditional logit because it controls for the panel structure of the data set and accounts for differences among individual preferences by estimating a normal distribution of taste heterogeneity for each preference parameter [22] 1 . The dependent variable was respondents' preferred treatment choice, and the explanatory variables included the levels of the five attributes. The choice model was estimated using NLOGIT 4.0 (Econometric Software, Inc., Plainview, NY, USA). Preference weights for patients and parents were estimated jointly using interactions to control for group differences.
For each attribute, we used effects coding (i.e., 1, 0, -1 for a three-level attribute instead of dummy coding 1, 0, 0), which allows estimation of a parameter for each attribute level [19, 23, 24] . With effects coding, the omitted categories (the levels coded as -1) are estimated as the negative sum of the included categories [19, 23, 24] , making the mean effect of the model zero [19] . The omitted category was the worst level for each attribute. We estimated the standard errors for each omitted category using the variance-covariance matrix for the included parameters. The parameter estimates for the treatment attributes from the model can be interpreted as the relative strength of preference or preference weight for each attribute level [13, 24] . Furthermore, for a combination of attribute levels, the utility is estimated by summing the relevant attribute-level parameter estimates [25] . For example, the estimate for '30-minute nebulizer two times a day' was the sum of the parameters for '30-minute nebulizer' and 'two times a day'. To be able to compare the preference weights across the adult patients and parents, the raw parameter estimates were scaled between 0 and 10. For the stated-adherence questions, we averaged the changes in the percentages of respondents who would be 95 % adherent for various changes in inhaled antibioticmedication administration features.
consented to participate in the survey. Of those eligible respondents who provided consent, 271 patients and 209 parents answered at least one treatment-choice question and were included in the final analysis (response rate 4.4 %). Table 1 summarizes the demographic and CF treatmentexperience characteristics for patients, for parents, and for the overall sample. Statistically significant differences between the samples included gender, age, employment, using airway clearance to manage CF symptoms, current forced expiratory volume in 1 second (FEV 1 ), personal FEV 1 goal, and agreement about skipping treatments if they become too burdensome. We compared our sample with a national CF patient registry of approximately 28,000 patients [26] . Our sample had fewer males (36 vs. 52 %), higher employment (64 vs. 45 %), and a lower mean FEV 1 (72 vs. 77). Figure 3 presents the preference weights for patients and parents. The vertical bars around each preference weight indicate the 95 % confidence interval (CI) around the mean estimate. If the CIs between adjacent levels of a single attribute do not overlap, the mean estimates are statistically different from each other at the 5 % level of significance or better. More tolerable features were logically preferred to less tolerable features. For both groups of respondents, taking the inhaled-antibiotic medication two times a day was preferred to taking it three times a day (P \ 0.05), and moderate dry cough was preferred to severe dry cough (P \ 0.05). For parents, the preference weights for cost were disordered between $100 and $150, but the difference between these two levels was not statistically significant (P [ 0.05).
Preference Weights
The relative importance of changes in the treatment features is indicated by the vertical distance between two levels [16] . For example, the relative importance of an improvement in a dry cough from severe to moderate was approximately 7.0 for patients and approximately 7.3 for parents. The relative importance of a 15-min reduction (from 30 to 15 min) per use of a nebulizer was approximately 2.2 for patients and approximately 1.3 for parents. Comparison of these relative importances indicates that an improvement in dry cough from severe to moderate is 3.2 times (7.0/2.2 = 3.2) more important for patients and 5.6 times (7.3/1.3 = 5.6) more important for parents than a 15-min reduction in the time required to use a nebulizer. Similarly, switching from a 30-min nebulizer twice daily to a 10-min DPI twice daily was 6.3 times more important for patients and 2.0 times more important for parents than an improvement in dry cough from moderate to mild. Table 2 presents the raw parameter estimates and standard deviations from the random-parameters logit model. Figure 4 shows the change in the percentages of respondents who would take their medication as prescribed 95 % of the time when presented with different treatment features. For all treatment profiles, 47 % of patients and 67 % of parents said they would be adherent 95 % of the time. When asked about the likely stated adherence of other people in a similar circumstance, only 26 % of patients and 34-39 % of parents (of children of different age categories) believed that others like them would be adherent 95 % of the time. For both groups of respondents, decreasing the time required for antibiotic treatments from 30 to 5 min had the largest effect on stated adherence, where 26 % more patients and 29 % more parents believed they would be 95 % adherent to treatments that took 5 min to complete, whereas for other people (adult patients of a similar age or other families with a pediatric CF patient) it would be 41 % more patients and 29-33 % more parents.
Similarly, 29 % more patients and 23 % more parents believed they would be 95 % adherent to treatments that used DPIs instead of nebulizers, whereas for other people it would be 34 % more patients and 25-31 % more parents. Both patients and parents believed that the impact of decreases in the time required for each use and switching from nebulizers to DPIs would be greater for other people than for themselves.
Discussion
This study found that inhaled-antibiotic devices with lower frequency of administration, shorter administration times for a given device, and milder dry cough were preferred. Over the attribute ranges used in the study design, the relative importance of administration frequency and device-specific time were similar, while mild or moderate dry cough was much more important than frequency and time. Higher values are associated with greater preferences. Only relative differences matter when interpreting preference weights. The differences between adjacent weights indicate the relative importance of moving from one level of an attribute to an adjacent level of that attribute. The vertical distance between the best and worst level (that is, difference in the model coefficients) of each attribute is a measure of the overall mean relative importance of that attribute (over the ranges presented in the survey). Note: The vertical bars surrounding each mean preference weight denote the 95 % confidence intervals about the point estimate. If the confidence intervals do not overlap for adjacent levels in a particular attribute, the mean estimates are statistically different from each other at the 5 % level of significance Preferred devices are associated with higher levels of stated adherence. While developing treatments with lower administration burden (lower frequency of administration and shorter administration times) based on active ingredients with known efficacy and toxicity is an efficient way to develop new treatments [27] , most clinical trials are designed to collect evidence of treatment efficacy and safety relative to particular comparators, with little emphasis on non-clinical benefits such as time savings from reduced treatment burden. Yet, such non-clinical benefits can have significant effects on patients' quality of life. Patient satisfaction is expected to be higher for treatments with lower administration burden, all other things being equal. More satisfied patients are more likely to comply with dosing regimens when they perceive adherence burden to be relatively low compared with treatment benefits [28] . To the extent that better adherence is correlated with more effective control of chronic respiratory infections, more preferred devices could decrease the overall cost of treating CF patients [29] . In the USA, treating chronic P. aeruginosa infections increased annual medical expenditure by $US18,094 (year 2006 values) in patients aged \10 years and by $US24,312 in patients aged 30-64 years [30] .
Clinical trials often result in better adherence than in the real world because they are conducted under a controlled environment and for shorter durations than the actual time patients may use a treatment in the real world. Therefore, evidence of efficacy outcomes based on clinical trial data is likely to be a poor predictor of the actual effectiveness of a treatment in the real world when realized efficacy in the long run depends on long-term compliance. Verifying patient adherence to a treatment regimen is often timeconsuming, costly, and burdensome for participants. Therefore, the DCE method may be useful for other researchers in understanding the effect of administration burden on patient satisfaction and stated adherence in other therapeutic areas with a high treatment burden like CF. Although we demonstrated that respondents accepted trade-offs among administration features for inhaled-antibiotic medications, our study has some limitations. Primarily, respondents evaluated hypothetical treatments, and differences can arise between stated and actual choices. However, we have minimized the hypothetical bias by making the hypothetical choices mimic real-world tradeoffs as closely as possible and verified the attributes included in the survey during the survey testing. Second, although the sample was adequately powered to estimate preference parameters with good precision, the response rate for this study was low (\5 %), the physician diagnosis of CF and testing positive for P. aeruginosa was self-reported, and the online method of recruitment resulted in younger samples (mean age of the adult patients was 23 years and of parents was 32 years) [26] , which could have introduced selection bias. Moreover, the membership of the CFF may not be representative of the general CF population. Furthermore, we do not have data on the characteristics of non-respondents, respondents who did not meet the inclusion criteria, or respondents who did not consent to participate. Thus, the degree of potential selection bias cannot be determined. Finally, our cross-sectional study also measures stated adherence at one point in time and does not measure long-term stated or actual adherence.
Conclusion
Adherence to inhaled antibiotics that require a nebulizer is low [5, 6] . Alternative technologies such as DPIs could provide better adherence because of shorter administration and maintenance time. This study suggests that lower frequency of administration, shorter administration times for a given device, and milder dry cough may improve stated adherence to antibiotic treatment of CF lung infections.
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